IGF/IBP-2-13 (Haemopep)

N/A

Report date: 2025/03/20 20:00:06
NME

Base Information

Drug NameIGF/IBP-2-13 (Haemopep)
Drug Alias Namediabetes therapeutics (Haemopep)
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionSomatomedin receptors antagonists
TargetsSomatomedin receptors
Therapy Area/IndicationsObesityDiabetes Mellitus
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryGermany
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesHaemopep Pharma GmbH
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesHaemopep Pharma GmbH
Active IndicationsN/A
Inactive IndicationsObesityDiabetes Mellitus

Other Information

ATC CodeN/A
Related LinksN/A